The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection

抗体和 Fc 新生儿受体在传播/创始菌株选择中的作用

基本信息

  • 批准号:
    9089719
  • 负责人:
  • 金额:
    $ 73.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-06-15 至 2020-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Env-specific IgG markedly enhances HIV-1 and SIV transcytosis across genital and gut epithelial cells in vitro. The enhanced transcytosis is mediated by the Fc neonatal receptor (FcRn), which binds lgG-containing immune complexes (ICs) at low pH, shuttles them through epithelial cells, and releases them at neutral pH. We found that with four different vaccine regimens, FcRn-mediated transcytosis activity in serum of vaccinated macaques strongly correlated with the number of T/F variants infecting the animals after repeated low-dose SIVmac251 rectal challenges. Moreover, with ALVAC-based vaccine regimens that provided up to 40% protection, animals with high vaccine-induced serum FcRn-mediated transcytosis activity became infected with fewer challenges than those with low activity, and animals that remained uninfected always had very low activity. Thus, vaccines simultaneously protected some animals while driving infection and more T/F strains in others. We address this conundrum and so seek to understand relationships between beneficial and deleterious antibodies by testing the following hypothesis: 1) relative levels of vaccine-induced antiviral and enhancing antibodies are key determinants of T/F variant selection and infection acquisition. We will also explore why, mechanistically, FcRn-mediated transcytosis so strongly impacts infection. FcRn only binds well to IgG or ICs at low pH (=~6.5), and our preliminary data indicate that macaque rectal secretions are infrequently acidic. However, Fcγ receptors (FcγRs), which bind ICs at neutral pH, are expressed along with FcRn in macaque rectal epithelial cells. In view of these and other observations, we propose a novel hypothesis: 2) infectious ICs enter rectal epithelial cells via FcγRs at the usually pH-neutral rectal mucosa, followed by FcRn-dependent delivery to subepithelial tissue where infection occurs. To test these hypotheses we will accomplish the following: Specific Aim 1. Delineate relationships between antiviral antibodies, enhancing antibodies, T/F strain selection, and infection outcome following ALVAC-SIV/gp120 vaccination. We will measure the breadth and potency of vaccine-induced neutralizing, ADCC, virus-capturing, and FcRn-mediated enhancing antibodies in serum and rectal IgG against a panel of T/F strains that established infection after repeated low dose SIVmac251 rectal challenge. We will also model T/F selection in vitro with a novel approach. Specific Aim 2. Determine the mechanisms underlying the association between FcRn-mediated transcytosis and infection outcomes. Using engineered cells and rectal tissue explants, we will determine if SIV- or HIV-1-ICs are internalized via FcγRs prior to FcRn-dependent shuttling across the epithelium. We have uncovered a unique antibody activity that is strongly associated with infection outcome following vaccination. Defining the implications and mechanisms of this activity could lead to new insights into how opposing antibody functions interact with each other, to novel targets for microbicides, and to vaccine strategies that elicit maximal antiviral responses with minimal deleterious effects.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donald N Forthal其他文献

Donald N Forthal的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donald N Forthal', 18)}}的其他基金

The impact of antibody and pH on female-to-male SIV infection
抗体和pH值对女性对男性SIV感染的影响
  • 批准号:
    8688891
  • 财政年份:
    2012
  • 资助金额:
    $ 73.73万
  • 项目类别:
The impact of antibody and pH on female-to-male SIV infection
抗体和pH值对女性对男性SIV感染的影响
  • 批准号:
    8876564
  • 财政年份:
    2012
  • 资助金额:
    $ 73.73万
  • 项目类别:
The impact of antibody and pH on female-to-male SIV infection
抗体和pH值对女性对男性SIV感染的影响
  • 批准号:
    8410404
  • 财政年份:
    2012
  • 资助金额:
    $ 73.73万
  • 项目类别:
The impact of antibody and pH on female-to-male SIV infection
抗体和pH值对女性对男性SIV感染的影响
  • 批准号:
    8505379
  • 财政年份:
    2012
  • 资助金额:
    $ 73.73万
  • 项目类别:
Rodent Animal Biosafety Level 3 (ABSL3)
啮齿类动物生物安全 3 级 (ABSL3)
  • 批准号:
    8260272
  • 财政年份:
    2011
  • 资助金额:
    $ 73.73万
  • 项目类别:
PSWRCE Cpmprehensive Program Training Program for High Containment Lab
PSWRCE 高密闭实验室 CPM 综合项目培训计划
  • 批准号:
    8260273
  • 财政年份:
    2011
  • 资助金额:
    $ 73.73万
  • 项目类别:
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
针对嵌合病毒宿主抗原的广泛反应性抗体
  • 批准号:
    8465819
  • 财政年份:
    2010
  • 资助金额:
    $ 73.73万
  • 项目类别:
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
针对嵌合病毒宿主抗原的广泛反应性抗体
  • 批准号:
    8089308
  • 财政年份:
    2010
  • 资助金额:
    $ 73.73万
  • 项目类别:
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
针对嵌合病毒宿主抗原的广泛反应性抗体
  • 批准号:
    7984238
  • 财政年份:
    2010
  • 资助金额:
    $ 73.73万
  • 项目类别:
Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
针对嵌合病毒宿主抗原的广泛反应性抗体
  • 批准号:
    8279451
  • 财政年份:
    2010
  • 资助金额:
    $ 73.73万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 73.73万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了